Boehringer Ingelheim previously announced a multi-program option and license agreement with Sino Biopharmaceutical involving six pre-clinical oncology biologics. Sino Biopharmaceutical’s subsidiaries ...
Source LinkBoehringer Ingelheim previously announced a multi-program option and license agreement with Sino Biopharmaceutical involving six pre-clinical oncology biologics. Sino Biopharmaceutical’s subsidiaries ...
Source Link
Comments